Shots:
- AstraZeneca to receive up front & development, regulatory and commercial milestones along with royalties. The agreement will provide a novel compound into Sierra’s pipeline to supply therapies for patients with rare cancers
- Sierra plans to initiate a P-II study of momelotinib (JAK inhibitor) + AZD5153 (BRD4 BET inhibitor) in patients with myelofibrosis & will be responsible for global development. The trial is expected to start in H1’22
- Momelotinib is currently being evaluated in the P-III MOMENTUM clinical trial for symptomatic and anemic myelofibrosis patients and has received the US FDA’s FTD for the same. The results are expected in Q1’22
Click here to read full press release/ article | Ref: Sierra Oncology | Image: Sierra Oncology
The post AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis first appeared on PharmaShots.
